Actively Recruiting
Novel Targetable BIOmarkers in ANorexia NervosA
Led by University Hospital, Basel, Switzerland · Updated on 2024-12-12
32
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Basel, Switzerland
Lead Sponsor
U
University of Zurich
Collaborating Sponsor
AI-Summary
What this Trial Is About
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.
CONDITIONS
Official Title
Novel Targetable BIOmarkers in ANorexia NervosA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 60 years
- Written informed consent provided
- Confirmed diagnosis of restrictive type Anorexia Nervosa with BMI between 10 and 16 kg/m2 for patient groups
- Healthy control participants aged 18 to 60 years with BMI between 19 and 24.9 kg/m2
- Patients include both exercising and non-exercising subtypes of restrictive Anorexia Nervosa
You will not qualify if you...
- Use of antibiotics within the last 31 days
- Current illicit drug abuse including daily marijuana or cannabidiol use
- Consumption of more than 24 g of alcohol per day
- Any severe chronic disease other than Anorexia Nervosa (e.g., active cancer)
- Severe kidney impairment not caused by Anorexia Nervosa (e.g., estimated glomerular filtration rate <30 ml/min/m2)
- Known liver cirrhosis or severe liver impairment not caused by Anorexia Nervosa
- Acute upper respiratory tract infection within the last 31 days
- Uncontrolled thyroid disorders
- Uncontrolled high blood pressure
- Current pregnancy, breastfeeding, or undergoing in vitro fertilization treatment
- Inability to understand study information or follow study procedures due to language barriers, psychological disorders, dementia, or similar conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
K
Katharina Timper, Prof.
CONTACT
V
Valerie Mettraux
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here